Medunik
NJ - PrincetonBiotechnology
Focus: Medunik is a rare disease-focused biotechnology company headquartered in Princeton, NJ, specializing in treatments for metabolic and genetic disorders. The company derives 83% of revenue from Sodium Phenylbutyrate, indicating a highly concentrated portfolio dependent on a single therapeutic area.
Profile data last refreshed 19h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Medunik
AI assessmentNot HiringNo open roles listed right now. Follow Medunik to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$3M Part DDeclining
Post-LOE
Dominant revenue driver at 83% of portfolio, but ANDA post-LOE status indicates generic competition and margin erosion.
Help build intelligence for Medunik
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.